Cargando…
Loss of p16 does not protect against premature ovarian insufficiency caused by alkylating agents
BACKGROUND: Chemical agents such as alkylating agents (AAs) that are commonly used for the treatment of cancer cause great damage to the ovaries, thereby significantly increasing the risk of premature ovarian insufficiency (POI). However, the exact molecules underlying AA-induced POI remain largely...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9993597/ https://www.ncbi.nlm.nih.gov/pubmed/36890528 http://dx.doi.org/10.1186/s12884-023-05476-x |